Trastuzumab deruxtecanis a human epidermal growth factor receptor 2 (HER2)-directed antibody and topoisomerase inhibitor conjugate. The new drug targets the HER2 protein and is linked to a topoisomerase inhibitor, which is cytotoxic. "There have been many advances in the development of drugs for H...
NEW STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOFA conjugate and preparation method therefor, comprising a medication composition comprising the conjugate and a use of the medication composition in preparing medications for the treatment or prevention of diseases.Gang Qin...
Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther 2012; 11: 224-34.SharkeyRM,GovindanSV,CardilloTM,etal.Epratuzumab SN 38: a new antibody drug conjugate for the therapy of... RM Sharkey,SV Govindan,TM Cardillo,... - 《Molecular...
CD13 as a new tumor target for antibody-drug conjugates: Validation with the conjugate MI130110 solid tumors.Anti-CD13 monoclonal antibody (mAb) TEA1/8 has been used to prepare a novel ADC, MI130110, by conjugation to the marine compound PM0... JM Domínguez,G Pérez-Chacón,MJ Guillén...
抗体偶联药物(Antibody-drug conjugate, ADC)借助抗体将高活性载荷药物选择性地递送到肿瘤细胞,以达到治疗肿瘤的目的。因其高靶向性和宽治疗窗的特点,ADC药物被称作“魔术子弹”,受到广泛关注。特别是ADC药物Enhertu在Her2阳性乳腺癌和胃癌患者中表现出的卓越疗效,进一步点燃了业界对于ADC抗肿瘤药物研发的热情。从临床...
ADCETRIS (brentuximab vedotin) is a CD30-directed antibody鈥揹rug conjugate (ADC). When it was approved by the Food and Drug Administration (FDA) in August 2011, it became only the second ADC approved by the FDA and the only one on the market at that time following the withdrawal of ...
Antibody-drug Conjugates“Since the establishment of GeneQuantum we have focused on the development of innovative bioconjugate drugs represented by Antibody-drug-Conjugate. We’ve developed highly differentiated ADC technology platforms, including enzyme-catalyzed site-specific conjugation technology, i...
Data highlights potential of Hummingbird Bioscience’s dual-payload antibody-drug conjugate platform to improve upon the current generation of ADCs
Pfizer’s Inotuzumabozogamicin (Besponsa) is an antibody-drug conjugate (ADC) that enables small molecule toxin to precisely kill CD22-overexpressing cancer cells by its targeting. The drug was approved by the EU in June 2017, which is the fourth approved ADC, leading to increased confidence in...
antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 ...